Ankylosing Spondylitis Clinical Trial
Official title:
The Relationship Between Systemic Immune Inflammation Index and Disease Activity in Patients With Ankylosing Spondylitis
NCT number | NCT06094673 |
Other study ID # | IstPRMTRH4 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | June 1, 2023 |
Est. completion date | July 2, 2023 |
In this study, the aim was to investigate the relationship between SII and other laboratory parameters with disease activity in AS patients and to discuss its usability in the follow-up and treatment process.
Status | Completed |
Enrollment | 90 |
Est. completion date | July 2, 2023 |
Est. primary completion date | July 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Patients between the ages of 18 and 65 who have been diagnosed with Ankylosing Spondylitis according to the Modified New York Criteria, have applied to the Istanbul Physical Medicine and Rehabilitation Training and Research Hospital outpatient clinic on the specified dates, meet the exclusion criteria, and have complete blood count, CRP, and ESR values in their hospital records. Exclusion Criteria: - Presence of acute or chronic infection - Presence of autoimmune diseases other than Ankylosing Spondylitis - Pregnancy - Diabetes - Chronic kidney disease - Chronic liver disease - Malignancy - Cardiovascular disease - Hematological disease |
Country | Name | City | State |
---|---|---|---|
Turkey | Istanbul Physical Therapy and Rehabilitation Research and Training Hospital | Istanbul | Bahcelievler |
Lead Sponsor | Collaborator |
---|---|
Istanbul Physical Medicine Rehabilitation Training and Research Hospital |
Turkey,
Choe JY, Lee CU, Kim SK. Association between Novel Hematological Indices and Measures of Disease Activity in Patients with Rheumatoid Arthritis. Medicina (Kaunas). 2023 Jan 6;59(1):117. doi: 10.3390/medicina59010117. — View Citation
Liang T, Chen J, Xu G, Zhang Z, Xue J, Zeng H, Jiang J, Chen T, Qin Z, Li H, Ye Z, Nie Y, Zhan X, Liu C. Platelet-to-Lymphocyte Ratio as an Independent Factor Was Associated With the Severity of Ankylosing Spondylitis. Front Immunol. 2021 Nov 5;12:760214. — View Citation
Satis S. New Inflammatory Marker Associated with Disease Activity in Rheumatoid Arthritis: The Systemic Immune-Inflammation Index. Curr Health Sci J. 2021 Oct-Dec;47(4):553-557. doi: 10.12865/CHSJ.47.04.11. Epub 2021 Dec 31. — View Citation
Seng JJB, Kwan YH, Low LL, Thumboo J, Fong WSW. Role of neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and mean platelet volume (MPV) in assessing disease control in Asian patients with axial spondyloarthritis. Biomarkers. 2018 M — View Citation
Wu J, Yan L, Chai K. Systemic immune-inflammation index is associated with disease activity in patients with ankylosing spondylitis. J Clin Lab Anal. 2021 Sep;35(9):e23964. doi: 10.1002/jcla.23964. Epub 2021 Aug 21. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Systemic Immune Inflammation Index (SII) | The Systemic Immune Inflammation Index (SII) was calculated by dividing the product of neutrophil and platelet counts by the lymphocyte count. | through study completion, an average of 1 month | |
Primary | Neutrophil-to-lymphocyte ratio (NLR) | NLR is a ratio between the absolute neutrophil count and absolute lymphocyte count. | through study completion, an average of 1 month | |
Primary | Platelet to-lymphocyte ratio (PLR) | PLR is a ratio between the absolute platelet count and absolute lymphocyte count. | through study completion, an average of 1 month | |
Primary | Mean platelet volume (MPV) | MPV blood test measures the average size of patient's platelets | through study completion, an average of 1 month | |
Primary | Red blood cell distribution width (RDW) | A red cell distribution width (RDW) test measures the differences in the volume and size of the red blood cells (erythrocytes). | through study completion, an average of 1 month | |
Secondary | C-reactive protein | C-reactive protein (CRP) is a protein made by the liver. The level of CRP increases when there's inflammation in the body. | through study completion, an average of 1 month | |
Secondary | Erythrocyte sedimentation rate | The erythrocyte sedimentation rate (sedimentation rate, sed rate, or ESR for short) is a commonly performed hematology test that may indicate and monitor an increase in inflammatory activity within the body caused by one or more conditions such as autoimmune disease, infections, or tumors | through study completion, an average of 1 month | |
Secondary | The Bath Ankylosing Spondylitis Disease Activity Index | The index indicates that disease activity of AS patients. Higher scores indicate that higher activity | through study completion, an average of 1 month | |
Secondary | The Bath Ankylosing Spondylitis Functional Index | The index helps to evaluate disease activity of AS patients. High scores indicate that worse functional status. | through study completion, an average of 1 month | |
Secondary | The Bath Ankylosing Spondylitis Metrology Index | The index helps to evaluate spinal mobility of AS patients. Higher scores indicate more limited mobility. | through study completion, an average of 1 month | |
Secondary | Ankylosing Spondylitis Disease Activity Score with erythrocyte sedimentation rate | it helps to evaluate disease activity of AS patients by used to esr | through study completion, an average of 1 month | |
Secondary | Ankylosing Spondylitis Disease Activity Score with c-reactive protein | it helps to evaluate disease activity of AS patients by used to crp | through study completion, an average of 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02685904 -
A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis
|
Phase 3 | |
Completed |
NCT02186873 -
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
|
Phase 3 | |
Completed |
NCT01668004 -
The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)
|
Phase 4 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Completed |
NCT01934933 -
Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis
|
Phase 4 | |
Not yet recruiting |
NCT04875299 -
Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients
|
||
Completed |
NCT02763111 -
Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis
|
Phase 2 | |
Completed |
NCT02758782 -
NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis
|
Phase 4 | |
Active, not recruiting |
NCT02687620 -
Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
|
||
Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
Completed |
NCT01750528 -
Prevalence and Progression of Periodontitis in Ankylosing Spondylitis
|
N/A | |
Completed |
NCT01463189 -
Web-based Support to Manage Arthritis Pain
|
Phase 2 | |
Completed |
NCT01091675 -
Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs
|
Phase 3 | |
Completed |
NCT00844805 -
Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
|
Phase 3 | |
Recruiting |
NCT00747578 -
Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan
|
N/A | |
Completed |
NCT00715091 -
Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis
|
Phase 4 | |
Completed |
NCT01083693 -
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
|
N/A | |
Not yet recruiting |
NCT00517101 -
Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy
|
N/A | |
Completed |
NCT00367211 -
Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.
|
Phase 3 | |
Completed |
NCT00133315 -
TNFalfa Blocking Treatment of Spondylarthropathies
|
Phase 4 |